Scholarlink

Background <p>Red blood cell distribution width to platelet count ratio (RPR) has garnered increasing attention as a novel inflammation marker. However, its association with cardiovascular events (CVE) in end-stage renal disease patients undergoing peritoneal dialysis (PD) is largely unknown.</p> Method <p>1,222 PD patients, from 4 centers, were retrospectively recruited between January 1, 2012-December 31, 2017. Baseline data were collected ~ 3 months after starting PD treatment, and patients divided into 2 groups (low RPR [<i>n</i> = 710], high RPR [<i>n</i> = 512]), based on the optimal RPR cut-off of 0.084 identified by receiver operating characteristic curve analysis. The relationship between RPR with new CVE, cardiovascular disease mortality, and all-cause mortality was analyzed using restricted cubic spline (RCS) and Kaplan-Meier survival curve analyses. Associations between RPR and patient characteristics were identified using uni- and multi-variate Cox logistic regression analyses, adjusted for baseline patient characteristics, co-morbidities, and laboratory parameters. Competitive risk analysis was conducted to assess the effects of other follow-up endpoint events on CVEs.</p> Results <p>77 new CVEs and 212 deaths occurred during the follow-up period. High RPR, versus low, had significantly higher rates of new CVEs under Kaplan-Meier analysis; this was still present even after adjusting for specific baseline characteristics, co-morbidities, and laboratory parameters under multivariate Cox regression analysis. RCS analysis also revealed that the relationship between RPR and CVE was non-linear, with RPR ~ 0.06–0.15 being associated with higher CVE risk.</p> Conclusion <p>Higher RPR may serve as an independent prognostic marker for CVE risk in PD patients, providing a non-invasive, cost-effective marker for early CVE detection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Higher red blood cell distribution width to platelet count ratio is associated with increased cardiovascular events in peritoneal dialysis patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月28日

查看全文
  • Jiadi Yu,
  • Liuzhen Li,
  • Na Tian,
  • Qingdong Xu,
  • Xiaojiang Zhan,
  • Fenfen Peng,
  • Xiaoyang Wang,
  • Ning Su,
  • Xiaoran Feng,
  • Xingming Tang,
  • Xianfeng Wu,
  • Qian Zhou,
  • Jianbo Liang,
  • Yueqiang Wen,
  • Jun Dong,
  • Jiao Li

摘要

Background

Red blood cell distribution width to platelet count ratio (RPR) has garnered increasing attention as a novel inflammation marker. However, its association with cardiovascular events (CVE) in end-stage renal disease patients undergoing peritoneal dialysis (PD) is largely unknown.

Method

1,222 PD patients, from 4 centers, were retrospectively recruited between January 1, 2012-December 31, 2017. Baseline data were collected ~ 3 months after starting PD treatment, and patients divided into 2 groups (low RPR [n = 710], high RPR [n = 512]), based on the optimal RPR cut-off of 0.084 identified by receiver operating characteristic curve analysis. The relationship between RPR with new CVE, cardiovascular disease mortality, and all-cause mortality was analyzed using restricted cubic spline (RCS) and Kaplan-Meier survival curve analyses. Associations between RPR and patient characteristics were identified using uni- and multi-variate Cox logistic regression analyses, adjusted for baseline patient characteristics, co-morbidities, and laboratory parameters. Competitive risk analysis was conducted to assess the effects of other follow-up endpoint events on CVEs.

Results

77 new CVEs and 212 deaths occurred during the follow-up period. High RPR, versus low, had significantly higher rates of new CVEs under Kaplan-Meier analysis; this was still present even after adjusting for specific baseline characteristics, co-morbidities, and laboratory parameters under multivariate Cox regression analysis. RCS analysis also revealed that the relationship between RPR and CVE was non-linear, with RPR ~ 0.06–0.15 being associated with higher CVE risk.

Conclusion

Higher RPR may serve as an independent prognostic marker for CVE risk in PD patients, providing a non-invasive, cost-effective marker for early CVE detection.